Remove AFIB Remove Arrhythmia Remove Outcomes
article thumbnail

Colchicine Not the Answer for Recurring Arrhythmias After Ablation

Med Page Today

(MedPage Today) -- For patients undergoing catheter ablation for atrial fibrillation (Afib), there was no signal that a brief course of colchicine reduced atrial arrhythmia recurrence or improved clinical outcomes when taken for 10 days starting.

article thumbnail

Cardiomatics guide: Analyzing arrhythmias made easy

Cardiomatics

By understanding the nuances of abnormalities detected in Cardiomatics and interpreting detailed reports, healthcare professionals can intervene promptly to prevent adverse outcomes. AFIB/AFL – atrial fibrillation or atrial flutter episodes. 1] Arrhythmia Recognition: The Art of Interpretation, T.Garcia, D.Garcia.

article thumbnail

Arrhythmia Recurrence & Rhythm Control after Catheter Ablation for AFib; Transthyretin Amyloid Cardiomyopathy & Tafamidis; Sodium Restriction & BP

American College of Cardiology

In this weeks View, Dr. Eagle looks at arrhythmia recurrence and rhythm control after catheter ablation for atrial fibrillation. He then discusses long-term outcomes in transthyretin amyloid cardiomyopathy in patients treated with tafamidis.

article thumbnail

Volta Medical Enters into Joint Development Agreement with GE HealthCare to Support Electrophysiologists Treating Atrial Fibrillation

DAIC

Volta Medical has announced it has entered into a Joint Development Agreement with GE Healthcare to enhance arrhythmia procedures with artificial intelligence (AI)-driven electrophysiology technologies. 1 Approximately 33 million patients worldwide are living with AFib.

article thumbnail

PO-02-080 DIRECT-FROM-ECG APNEA-HYPOPNEA INDEX (AHI) FOR IMPROVING AFIB AND OBSTRUCTIVE SLEEP APNEA PATIENT OUTCOMES

HeartRhythm

Nearly 50% of patients with AFib have comorbid obstructive sleep apnea (OSA), and 75% of OSA patients report some form of arrhythmia. Untreated OSA increases likelihood of poor outcomes for AFib patients including failed treatment, heart failure, and sudden cardiac death.

AFIB 40
article thumbnail

CTA and ACC Collaborate to Tackle Cardiovascular Disease with Technology

DAIC

CTA and the ACC recognize there is strong potential for cardiac monitoring (through Consumer Cardiovascular Technology Solutions) to help identify and screen patients with Atrial Fibrillation (AFib) and related arrhythmias to alert the right clinical groups for early support and reduction in mortality rates.

article thumbnail

Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE Platform for the Treatment of Paroxysmal Atrial Fibrillation

DAIC

a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTec h i , announced the submission of the VARIPULSE Platform for Premarket Approval Application (PMA) to the U.S. Twelve-month outcomes data from the pilot phase of the admIRE study, which assessed the safety and efficacy of the VARIPULSE Platform among U.S.